Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
1995-07-01
|
Series: | Journal of Lipid Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520397339 |
id |
doaj-aaa82e1cec014fadb9102ce077fdd3b8 |
---|---|
record_format |
Article |
spelling |
doaj-aaa82e1cec014fadb9102ce077fdd3b82021-04-26T05:50:02ZengElsevierJournal of Lipid Research0022-22751995-07-0136714631473Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosisB F Burkey0D France1H Wang2X Ma3B Brand4C Abuhani5M R Diffenderfer6J B Marsh7J R Paterniti, Jr8E A Fisher9Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a transgenic rat model of human apoA-I expression on the hyperlipoproteinemia and edema after puromycin aminonucleoside-induced nephrosis in three groups of animals: low line (TgR[hAI]low, human plasma apoA-I = 16.0 mg/dl); high line (TgR[hAI]high, 284 mg/dl); and non-transgenic litter mates (TgR[hAI]non). Nephrosis increased total plasma apoA-I levels 2-fold in TgR[hAI]non rats (75 vs. 162 mg/dl) and 4-fold in the TgR[hAI]low (97 vs. 458 mg/dl) and TgR[hAI]high rats (356 vs. 1,346 mg/dl). In both transgenic lines, this increase was due mainly to elevations of serum human apoA-I. The hepatic steady-state levels of rat apoA-I mRNA increased 5- to 7-fold in all three groups, while human apoA-I mRNA levels increased 21- and 65-fold in the low and high expressing groups, respectively, indicating a different degree of responsiveness of the rat and human genes. While nephrotic TgR[hAI]non and TgR[hAI]low rats showed severe hyperlipoproteinemia and edema, much lower levels of edema and of serum triglycerides, phospholipids, and cholesterol were seen in the TgR[hAI]high group. Urinary excretion of apoA-I, phospholipids, and cholesterol was significantly increased in the TgR[hAI]high group, indicating this as one possible mechanism for the relatively lower serum levels of these lipids. We conclude that the human apoA-I gene is responsive to nephrosis and that human apoA-I-transgenic rats with this syndrome provide an animal model for the study of human high density lipoprotein and apoA-I metabolism.http://www.sciencedirect.com/science/article/pii/S0022227520397339 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
B F Burkey D France H Wang X Ma B Brand C Abuhani M R Diffenderfer J B Marsh J R Paterniti, Jr E A Fisher |
spellingShingle |
B F Burkey D France H Wang X Ma B Brand C Abuhani M R Diffenderfer J B Marsh J R Paterniti, Jr E A Fisher Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis Journal of Lipid Research |
author_facet |
B F Burkey D France H Wang X Ma B Brand C Abuhani M R Diffenderfer J B Marsh J R Paterniti, Jr E A Fisher |
author_sort |
B F Burkey |
title |
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
title_short |
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
title_full |
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
title_fullStr |
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
title_full_unstemmed |
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
title_sort |
overexpression of human apolipoprotein a-i in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
1995-07-01 |
description |
Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a transgenic rat model of human apoA-I expression on the hyperlipoproteinemia and edema after puromycin aminonucleoside-induced nephrosis in three groups of animals: low line (TgR[hAI]low, human plasma apoA-I = 16.0 mg/dl); high line (TgR[hAI]high, 284 mg/dl); and non-transgenic litter mates (TgR[hAI]non). Nephrosis increased total plasma apoA-I levels 2-fold in TgR[hAI]non rats (75 vs. 162 mg/dl) and 4-fold in the TgR[hAI]low (97 vs. 458 mg/dl) and TgR[hAI]high rats (356 vs. 1,346 mg/dl). In both transgenic lines, this increase was due mainly to elevations of serum human apoA-I. The hepatic steady-state levels of rat apoA-I mRNA increased 5- to 7-fold in all three groups, while human apoA-I mRNA levels increased 21- and 65-fold in the low and high expressing groups, respectively, indicating a different degree of responsiveness of the rat and human genes. While nephrotic TgR[hAI]non and TgR[hAI]low rats showed severe hyperlipoproteinemia and edema, much lower levels of edema and of serum triglycerides, phospholipids, and cholesterol were seen in the TgR[hAI]high group. Urinary excretion of apoA-I, phospholipids, and cholesterol was significantly increased in the TgR[hAI]high group, indicating this as one possible mechanism for the relatively lower serum levels of these lipids. We conclude that the human apoA-I gene is responsive to nephrosis and that human apoA-I-transgenic rats with this syndrome provide an animal model for the study of human high density lipoprotein and apoA-I metabolism. |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520397339 |
work_keys_str_mv |
AT bfburkey overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT dfrance overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT hwang overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT xma overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT bbrand overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT cabuhani overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT mrdiffenderfer overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT jbmarsh overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT jrpaternitijr overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis AT eafisher overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis |
_version_ |
1721508439285301248 |